Pigmented Villonodular Synovitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Pigmented Villonodular Synovitis - Pipeline Review, H1 2016', provides an overview of the Pigmented Villonodular Synovitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis - The report reviews pipeline therapeutics for Pigmented Villonodular Synovitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pigmented Villonodular Synovitis therapeutics and enlists all their major and minor projects - The report assesses Pigmented Villonodular Synovitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pigmented Villonodular Synovitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Pigmented Villonodular Synovitis Overview 7 Therapeutics Development 8 Pipeline Products for Pigmented Villonodular Synovitis - Overview 8 Pigmented Villonodular Synovitis - Therapeutics under Development by Companies 9 Pigmented Villonodular Synovitis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Pigmented Villonodular Synovitis - Products under Development by Companies 12 Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development 13 F. Hoffmann-La Roche Ltd. 13 Five Prime Therapeutics, Inc. 14 Novartis AG 15 Plexxikon Inc. 16 Pigmented Villonodular Synovitis - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 emactuzumab - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 FPA-008 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 MCS-110 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 nilotinib - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 pexidartinib - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 PLX-73086 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Pigmented Villonodular Synovitis - Recent Pipeline Updates 38 Pigmented Villonodular Synovitis - Product Development Milestones 45 Featured News & Press Releases 45 May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis 45 Jan 13, 2016: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis 45 Jul 13, 2015: Five Prime Therapeutics Initiates Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis 46 Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis 46 May 14, 2014: Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting 47 May 14, 2014: Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis 48 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 50 Disclaimer 51
List of Tables
Number of Products under Development for Pigmented Villonodular Synovitis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Pigmented Villonodular Synovitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 13 Pigmented Villonodular Synovitis - Pipeline by Five Prime Therapeutics, Inc., H1 2016 14 Pigmented Villonodular Synovitis - Pipeline by Novartis AG, H1 2016 15 Pigmented Villonodular Synovitis - Pipeline by Plexxikon Inc., H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 25 Pigmented Villonodular Synovitis Therapeutics - Recent Pipeline Updates, H1 2016 38
List of Figures
Number of Products under Development for Pigmented Villonodular Synovitis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Targets, H1 2016 18 Number of Products by Stage and Targets, H1 2016 18 Number of Products by Mechanism of Actions, H1 2016 20 Number of Products by Stage and Mechanism of Actions, H1 2016 20 Number of Products by Routes of Administration, H1 2016 22 Number of Products by Stage and Routes of Administration, H1 2016 22 Number of Products by Molecule Types, H1 2016 24 Number of Products by Stage and Molecule Types, H1 2016 24
Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmaceRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and productRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.